SFX by Ex Libris Inc.

Title:	Protein Engineering Thrombin for Optimal Specificity and Potency of Anticoagulant Activity in Vivo
Source:	Biochemistry [0006-2960] Tsiang, M yr:1996

Basic

Full text

Full text available via American Chemical Society Journals

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Aird, William C C. "Natural anticoagulant inhibitors: activated Protein C." Baillière's best practice & research. Clinical haematology 17.1: 161-182.
description	2.	Rosenberg, R D D. "Natural anticoagulant mechanisms." The journal of clinical investigation 74.1 (1984): 1-6.
description	3.	Heumann, D. "Initial responses to endotoxins and Gram-negative bacteria." Clinica chimica acta 323.1-2 (2002): 59-72.
description	4.	Levi, Marcel, M. "Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation." Critical care medicine 29.7 (2001): -4.
description	5.	Mann, Henry J J. "Recombinant human activated protein C in severe sepsis." American journal of health-system pharmacy -23.
description	6.	Kurosawa, S. "Inflammation, sepsis, and coagulation." Haematologica 84.3 (1999): 254-9.
description	7.	Miyake, K. "Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2." Trends in microbiology 12.4: 186-192.
description	8.	Bradley, C. "Activated protein C in severe sepsis." Intensive and critical care nursing (2001): 177-178.
description	9.	Nieuwdorp, M. "Hypercoagulability in the metabolic syndrome." Current opinion in pharmacology 5.2 (2005): 155-9.
description	10.	Holst, O. "Biochemistry and cell biology of bacterial endotoxins." FEMS immunology and medical microbiology 16.2 (1997): 83-104.
description	11.	Taylor FB, G. "Activated protein C in sepsis." Journal of thrombosis and haemostasis 2.5 (2004): 708-717.
description	12.	McCoy, C. "Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis." Clinical therapeutics 25.2 (2003): 396-421.
description	13.	Deans, Katherine J J. "Substantiating the concerns about recombinant human activated protein C use in sepsis." Critical care medicine 2542-2543.
description	14.	Bone, R C C. "Sepsis: a new hypothesis for pathogenesis of the disease process." Chest 112.1 (1997): 235-43.
description	15.	Greisman, S E E. "Recombinant human activated protein C for severe sepsis." The New England journal of medicine 345.3 (2001): 219-219.
description	16.	O'Hagan, D T T. "Recent developments in adjuvants for vaccines against infectious diseases." Biomolecular engineering 18.3 (2001): 69-85.
description	17.	Franchini, M. "Recombinant factor VIIa. An update on its clinical use." Thrombosis and haemostasis 93.6: 1027-1035.
description	18.	Kuhlicke, J. "Hypoxia Inducible Factor (HIF)-1 Coordinates Induction of Toll-Like Receptors TLR2 and TLR6 during Hypoxia." PLOS One 2.12 (2007): 12-12.
description	19.	Esmon, Charles T T. "Crosstalk between inflammation and thrombosis." Maturitas 47.4 (2004): 305-14.
description	20.	Parkinson, John F F. "Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation." Inflammation & allergy - drug targets 5.2 (2006): 91-106.